Multi Cancer Early Detection Market Report 2026

Multi Cancer Early Detection Market Overview

• Multi Cancer Early Detection market size has reached to $1.73 billion in 2025 • Expected to grow to $3.84 billion in 2030 at a compound annual growth rate (CAGR) of 16.8% • Growth Driver: Shift Towards Personalized Medicine On The Multi-Cancer Early Detection Market • Market Trend: Innovations In Diagnostic Technologies Drive Advancements In The Multi-Cancer Early Detection Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Multi Cancer Early Detection Market?

Multi-cancer early detection is the detection and diagnosis of various types of cancer at an early stage by analyzing biomarkers and other indicators in bodily fluids or tissues. This approach aims to identify cancerous conditions across multiple organs or tissues before symptoms manifest, enabling timely intervention and improved treatment outcomes. The main types of multi cancer early detection are liquid biopsy, gene panel, laboratory developed tests (LDT), and others. Liquid biopsy is a non-invasive medical test that detects cancer-related biomarkers, such as circulating tumor cells (CTCs) or cell-free DNA (cfDNA), from bodily fluids like blood or urine, offering insights into cancer presence, progression, and treatment response. They are used for the diagnosis of various types of cancers including solid tumors and hematological malignancies by hospitals, diagnostic laboratories, and others.

What Is The Multi Cancer Early Detection Market Growth Forecast?

The multi cancer early detection market size is expected to see rapid growth in the next few years. It will grow to $3.84 billion in 2030 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to advancements in ngs-based diagnostics, increasing investments in precision oncology, rising adoption of ai-powered screening tools, expansion of national cancer screening initiatives, growing integration of multiomics in early detection. Major trends in the forecast period include increasing use of liquid biopsy technologies, rising adoption of comprehensive gene panel testing, growing focus on multi-organ cancer screening programs, expansion of biomarker discovery for early diagnosis, shift toward non-invasive diagnostic approaches.

What Is The Driver Of The Multi Cancer Early Detection Market?

A rising shift towards personalized medicine is expected to propel the growth of the multi-cancer early detection market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare decisions to the individual characteristics, needs, and genetic profile of each patient. The increasing demand for personalized medicine stems from its capacity to offer enhanced treatment efficacy, propelled by advancements in genomics, the rising complexity of diseases, and supportive regulatory measures. Personalized medicine enhances the effectiveness of multi-cancer early detection by customizing screening and treatment strategies according to individual genetic and biomarker profiles. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. It includes seven drugs tailored for cancer treatment and three targeting different diseases and conditions. Therefore, a rising shift towards personalized medicine is driving the multi-cancer early detection market.

Key Players In The Global Multi Cancer Early Detection Market

Major companies operating in the multi cancer early detection market are Illumina Inc., Sysmex Inostics GmbH, Exact Sciences Corporation, Natera Inc, Guardant Health, Core Diagnostics, Genecast Biotechnology Co. Ltd, Burning Rock Biotech Limited, Freenome Holdings Inc., Guangzhou AnchorDx Medical Co. Ltd, Singlera Genomics Incorporated, Lucence Health Inc., PredOmix Technologies, Micronoma INC., EarlyDiagnostics (EarlyDx), Elypta AB, Predictive Oncology, ANPAC Bio-Medical Science Co. Ltd, CanSense Ltd, Epigenomics AG, VolitionRX, OncoSeek, Laboratory for Advanced Medicine, Inc., AnchorDx

Global Multi Cancer Early Detection Market Trends and Insights

Major companies operating in the multi-cancer early detection market are developing ctDNA-based liquid biopsy tests to enhance sensitivity, specificity, and early detection rates, thereby improving patient outcomes. A ctDNA-based liquid biopsy test detects circulating tumor DNA in the bloodstream, providing a non-invasive means to monitor tumor dynamics, treatment response, and minimal residual disease or early recurrence. For instance, in May 2023, Lucence, a US-based cancer diagnostics manufacturer, launched LucenceINSIGHT, an innovative multi-cancer early detection (MCED) blood test, at their US headquarters. This innovative ctDNA-based liquid biopsy test offers screening for 10 prevalent cancers with just one blood sample. With 78% of global cancer fatalities attributed to types lacking routine screening recommendations, this blood test promises enhanced convenience and accessibility for asymptomatic individuals seeking screening across multiple cancer types.

What Are Latest Mergers And Acquisitions In The Multi Cancer Early Detection Market?

In May 2023, Freenome Holdings Inc., a US-based biotechnology company acquired Oncimmune Ltd. for an undisclosed amount. With this acquisition, Freenome aims to enhance its early cancer detection capabilities by integrating Oncimmune's autoantibody platform and expanding its multiomics portfolio. Oncimmune Ltd. is a UK-based biotechnology company that specializes in immunodiagnostics for cancer detection.

What Defines the Multi Cancer Early Detection Market?

The multi-cancer early detection market consists of revenues earned by entities by providing services such as screening tests, diagnostic imaging, molecular diagnostics, and risk assessment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The multi-cancer early detection market also includes sales of diagnostic kits, assay panels, reagents, instruments, software solutions for data analysis and interpretation, and quality control materials. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Multi Cancer Early Detection Market Report 2026?

The multi cancer early detection market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the multi cancer early detection industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.